オプションチェーンは、Medicus Pharmaの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Medicus Pharmaの市場センチメントを評価します。.

Medicus Pharma (NASDAQ:MDCX) 株価情報, オプションチェーン

Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.

Medicus Pharma Ltd

Medicus Pharma Ltd. - Warrant

WIIM

ADAP

Adaptimmune Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.

Needham analyst Mike Matson reiterates OncoCyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCX#NASDAQ">OCX</a>) with a Buy and maintains $4.25 price target.

News

Price Target

Reiteration

Analyst Ratings

Needham Reiterates Buy on OncoCyte, Maintains $4.25 Price Target

Earnings

Earnings Beats

Earnings Misses

LSTR

Landstar System Q1 EPS $0.85 Misses $0.99 Estimate, Sales $1.15B Beat $1.13B Estimate

SGMO

Sangamo Therapeutics shares are trading lower after the company reported worse-than-expected Q1 financial results.

Bridgemarq Real Estate (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BRE#TSX">BRE</a>) reported quarterly earnings of $0.20 per share. This is a 5.26 percent increase over earnings of $0.19 per share from the same period last year. The company reported $77.97 million in sales this quarter. This is a 562.62 percent increase over sales of $11.77 million the same period last year.

TSX:BRE

Bridgemarq Real Estate Q1 Adj. EPS $0.20 Up From $0.19 YoY, Sales $77.97M Up From $11.77M YoY

ITOS

Trading Halt: Halted at 7:50:00 a.m. ET - Trading Halt: Halt News Pending

Palmer Luckey, the virtual-reality prodigy who sold Oculus to Facebook for $2 billion in 2014, says that payday granted him entry to an ultra-exclusive group chat called the "B Boys Club."
What Happened: The only password to the group chat is a unicorn-level exit: founders must have sold a company for at least $1 billion. "It's all boys who have sold a company for at least $1 billion," Luckey <a href="https://www.youtube.com/watch?v=21I_3VEs0iI">told</a> Peter Diamandis on the "Moonshots" podcast. While he insists women aren't barred, none are in the thread.
That omission is striking given deals like L'Oréal's $1.2 billion purchase of IT Cosmetics from co-founder Jamie Kern Lima in 2016.
By club standards, Instagram's Kevin Systrom and Mike Krieger (<a href="https://www.benzinga.com/news/15/10/5891968/instagrams-fifth-anniversary-how-good-of-a-deal-was-this-for-facebook">sold</a> to Facebook for $1 billion in 2012) would qualify easily. So would WhatsApp's Jan Koum and Brian Acton, who <a href="https://www.benzinga.com/news/14/02/4322191/update-facebook-announces-16b-cash-stock-merger-with-whatsapp">fetched</a> $19 billion two years later. Slack co-founder Stewart Butterfield dwarfs them all, <a href="https://www.benzinga.com/analyst-ratings/analyst-color/20/12/18616683/6-salesforce-analysts-react-to-slack-deal-game-changer-potential">exiting</a> to Salesforce for $27.7 billion in 2021.
See also: <a href="https://www.benzinga.com/25/05/45370909/china-rejects-us-blame-for-fentanyl-crisis-calls-tariff-penalties-unreasonable-amid-easing-trade-tensions">China Rejects US Blame For Fentanyl Crisis, Calls Tariff Penalties Unreasonable Amid Easing Trade Tensions</a>
Some of the planet's richest men, however, are stuck on read. Meta chief Mark Zuckerberg, who&#8217;s worth roughly $226 billion by Bloomberg's latest count, never actually sold Facebook, so he's out, as are Bill Gates, Sam Altman and Warren Buffett.
What To Know: Luckey, now <a href="https://www.forbes.com/profile/palmer-luckey/">valued</a> by Forbes at about $2.5 billion thanks to defense-tech startup Anduril, spends his chat time "shaming" peers into using their fortunes for more than vintage race cars.
"Guys, you have so much money. Why are you not doing what you know is the right thing to do with this capital?" he recalled messaging.
Luckey believes founders should personally build the world they envision instead of outsourcing philanthropy. Some converts are redirecting cash; others, he concedes, still prefer the fast lane. "I'm not saying everyone should become a vigilante crime fighter, but why wouldn't you use your resources to do the thing that you know needs to be done?" Luckey said.
Image via Just dance/Shutterstock
Read next: <a href="https://www.benzinga.com/news/global/25/05/45369837/piers-morgan-tears-into-pakistani-expert-who-says-isi-didnt-know-osama-bin-laden-was-living-near-military-base-all-they-had-to-do-was-get-a-pair-of-binoculars">Piers Morgan Tears Into Pakistani Expert Who Says ISI &#8216;Didn&#8217;t Know&#8217; Osama Bin Laden Was Living Near Military Base: &#8216;All They Had To Do Was Get A Pair Of Binoculars&#8217;</a>

Tech

Oculus Founder Palmer Luckey Reveals He's In An Invite-Only Group Chat With Just One Entry Rule

Kohl's intends to use the net proceeds from the sale of the Notes in a series of transactions resulting in the repayment of borrowings under its revolving credit facility. Kohl's expects to borrow under its revolving credit facility to repay all of its 4.25% notes due 2025 at maturity.

Kohl's Plans $360M Senior Secured Notes Offering Due 2030, Cites Use Of Proceeds For Debt Repayment Strategy

Telsey Advisory Group analyst Dana Telsey maintains FIGS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIGS#NYSE">FIGS</a>) with a Market Perform and maintains $5 price target.

FIGS

Telsey Advisory Group Maintains Market Perform on FIGS, Maintains $5 Price Target

Nayax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYAX#NASDAQ">NYAX</a>) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.04 by 380 percent. This is a 230.61 percent increase over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $81.11 million which missed the analyst consensus estimate of $85.59 million by 5.23 percent. This is a 26.81 percent increase over sales of $63.96 million the same period last year.

NYAX

Nayax Q1 EPS $0.19 Beats $0.04 Estimate, Sales $81.11M Miss $85.59M Estimate

LSEA

Landsea Homes shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results. Also the company announced it entered into a definitive agreement to be acquired by New Home.

PLRZ

Polyrizon Launches Preclinical Studies For Intranasal Benzodiazepines Targeting $3.15B Acute Seizure Market

CNSP

CNS Pharmaceuticals shares are trading higher after the company announced the transfer from Cortice Biosciences of Orphan Drug Designation for TPI 287.

Chardan Capital analyst Rudy Li maintains Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy and maintains $55 price target.

XENE

Chardan Capital Maintains Buy on Xenon Pharmaceuticals, Maintains $55 Price Target

Needham analyst Chris Pierce reiterates Archer Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) with a Buy and maintains $13 price target.

ACHR

Needham Reiterates Buy on Archer Aviation, Maintains $13 Price Target

ARWR

Arrowhead Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.

"We are excited about the opportunites we're seeing across our business and look forward to driving further revenue growth and value for our shareholders in 2025. We continue to expect full year 2025 GAAP EPS to exceed $2.40 per diluted share, and full year 2025 non-GAAP adjusted EPS to exceed $2.80 per diluted share," Mr. Suzuki concluded.

Guidance

BKTI

CORRECTION: BK Technologies Affirm FY25 GAAP EPS Outlook Of More Than $2.40

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) with a Buy and lowers the price target from $50 to $45.

NGNE

HC Wainwright & Co. Maintains Buy on Neurogene, Lowers Price Target to $45

MVST

Microvast Holdings shares are trading higher after the company reported better-than-expected Q1 sales results.

Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Buy and maintains $60 price target.

Chardan Capital Maintains Buy on Arrowhead Pharma, Maintains $60 Price Target

Management

Press Releases

Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

Health Care

Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region

Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch

Medicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV)

Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)

Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Comments

Medicus Pharma

Medicus Pharma (MDCX) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル